• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

    19.32 -0.14 (-0.75%)
    Streaming Delayed Price Updated: 9:30 AM EDT, Aug 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 23,458
    Open 19.32
    Bid (Size) 19.04 (5,000)
    Ask (Size) 19.32 (200)
    Prev. Close 19.46
    Today's Range 19.32 - 19.45
    52wk Range 14.68 - 25.32
    Shares Outstanding 93,148,652
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    Sarepta (SRPT) Q2 2026 Earnings Call Transcript ↗
    Revenue fell 34% YoY as management narrows guidance and eyes 2027 growth. 
    Via The Motley Fool
    Topics Earnings Intellectual Property

    Performance

    YTD
    -9.4%
    -9.4%
    1 Month
    +21.6%
    +21.6%
    3 Month
    +15.8%
    +15.8%
    6 Month
    +1.8%
    +1.8%
    1 Year
    +5.8%
    +5.8%

    More News

    Read More
    News headline image
    Sarepta Therapeutics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Sarepta Therapeutics (NASDAQ:SRPT) Surges on Q2 Earnings Beat and Narrowed Outlook ↗
    Via Chartmill
    Topics Earnings
    Sarepta Therapeutics (NASDAQ:SRPT) Q1 2026 Earnings Beat Overshadowed by Revenue Dip ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
    Via Investor Brand Network
    NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Sarepta Therapeutics to Participate in Upcoming Investor Conferences
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    My Top 3 Biotech Stocks for May 2026 ↗
    Via The Motley Fool
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta (SRPT) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
    Via Investor Brand Network
    Topics Artificial Intelligence
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    Via Investor Brand Network
    News headline image
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    Via MarketMinute
    Topics Intellectual Property Lawsuit

    Frequently Asked Questions

    Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
    Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
    The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
    What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
    The current price of Sarepta Therapeutics, Inc. - Common Stock is 19.32
    When was Sarepta Therapeutics, Inc. - Common Stock last traded?
    The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 08/27/26 09:30 AM ET
    What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
    The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.80B
    How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
    Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.